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Case report Lack of correlation between pulmonary disease 
and cystic fibrosis transmembrane conductance 
regulator dysfunction in cystic fibrosis: a case 
report
Hara Levy*1,2,3, Carolynn L Cannon4, Daniel Asher1, Christopher García3, Robert H Cleveland2,5, Gerald B Pier2,3, 
MichaelR Knowles6 and Andrew A Colin7
Abstract
Introduction: Mutations in both alleles of the cystic fibrosis transmembrane conductance regulator gene result in the 
disease cystic fibrosis, which usually manifests as chronic sinopulmonary disease, pancreatic insufficiency, elevated 
sodium chloride loss in sweat, infertility among men due to agenesis of the vas deferens and other symptoms 
including liver disease.
Case presentation: We describe a pair of African-American brothers, aged 21 and 27, with cystic fibrosis. They were 
homozygous for a rare frameshift mutation in the cystic fibrosis transmembrane conductance regulator 3791delC, 
which would be expected to cause significant morbidity. Although 80% of cystic fibrosis patients are colonized with 
Pseudomonas aeruginosa by eight years of age, the older brother had no serum opsonic antibody titer to P. aeruginosa 
by age 13 and therefore would have failed to mount an effective antibody response to the alginate (mucoid 
polysaccharide) capsule of P. aeruginosa. He was not colonized with P. aeruginosa until 24 years of age. Similarly, the 
younger brother was not colonized with P. aeruginosa until age 20 and had no significant lung disease.
Conclusion: Despite a prevailing idea in cystic fibrosis research that the amount of functional cystic fibrosis 
transmembrane conductance regulator predicts clinical status, our results indicated that respiratory disease severity in 
cystic fibrosis exhibits phenotypic heterogeneity. If this heterogeneity is, in part, genetic, it is most likely derived from 
genes outside the cystic fibrosis transmembrane conductance regulator locus.
Introduction
Mutations in both alleles of the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene result in the
disease cystic fibrosis (CF), which manifests classically as
chronic sinopulmonary disease, pancreatic insufficiency,
elevated sodium chloride loss in sweat, infertility among
men is due to agenesis of the vas deferens and other
symptoms like liver disease. Except for patients with sig-
nificant liver disease, the primary disease morbidity is
linked to the chronic pulmonary infections and conse-
quent decline in lung function. CFTR mutations are clas-
sified as severe (class I-III mutations) or mild (class IV-V
mutations) based on their effect on protein synthesis and
function, implying that the less CFTR that is made or is
functional, the more severe the clinical course of a patient
with cystic fibrosis (CF) [1-4]. Importantly, none of the
CFTR mutations correlate with sweat chloride levels and
only few of the more than 1,500 identified mutations in
CFTR result in an expected respiratory disease pheno-
type in homozygous or compound heterozygous patients.
I t  i s  w e l l - a c c e p t e d  t h a t  t h e  d i v e r s i t y  o f  l u n g  d i s e a s e
among CF patients is not accounted for either by varia-
tion in CFTR mutations or by level of sweat chloride as
there is considerable phenotypic heterogeneity even in
patients with the same class of CFTR mutation. In this
report, we describe a pair of siblings with a mild CF phe-
notype, who are homozygous for the 3791delC mutation,
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a rare CFTR frameshift mutation found originally in an
African American patient with CF [5,6]. The review was
approved by the Children's Hospital's Institutional
Review Board. On the basis of its classification as a severe
mutation, the 3791delC mutation is expected to cause
significant morbidity, yet these brothers present with an
incongruously mild clinical course.
Case presentation
We present two African American brothers aged 24 and
20 years. Both siblings were diagnosed with CF based on
symptoms and confirmed by sweat iontophoresis. The
elder brother presented with meconium ileus at birth. His
sweat chloride level was 104 meq/L. His brother, who is
six years younger, had a sweat chloride level of 113 meq/
L. Both are pancreatic insufficient, as documented by low
stool elastase levels, but, with appropriate nutritional,
vitamin and enzyme supplementation. Each maintains a
BMI (body mass index) of 24.0. Genotyping (Genzyme
Corporation, Cambridge, MA and Ambry Genetics, Aliso
Viejo, CA) verifies homozygosity for the 3791delC muta-
tion. The semen analysis from older brother showed no
sperm. The younger brother, meanwhile, had no semen
analysis. Neither parent was available to give family his-
tory concerning consanguinity or blood samples for
genotyping.
While 80% of CF patients are colonized with
Pseudomonas aeruginosa by eight years of age [7,8], the
older brother, by age 13, had no serum opsonic antibody
titer to P. aeruginosa and therefore would fail to mount an
effective antibody response to the alginate (mucoid poly-
saccharide) capsule of P. aeruginosa. Still, he was not col-
onized with P. aeruginosa until he reached 24 years of age.
Similarly, the younger brother was not colonized with P.
aeruginosa until he was 20 years old and had no signifi-
cant lung disease. Figure 1 shows pulmonary function
results over 14 years and decline in pulmonary function
since colonization with P. aeruginosa. (See additional file
1: Figure 1: PFT_FEV1%_Predicted for pulmonary func-
tion results.) Except during two endobronchial exacerba-
tions each, FEV1 is >80% predicted, consistent with the
top quartile and normal lung function for age according
to the Epidemiological Study of Cystic Fibrosis (ESCF)
classification [9]. The brothers had sequential chest X-
rays (CXRs) scored by the Brasfield system [10] with
sequential FEV1 and FVC, by a predictive scoring system
developed from a large CF cohort [11,12] One brother
had 14 CXRs over a 12.5-year period (age four months to
12 years and nine months); the other had 20 CXRs over
18 years (age one month to 18 years, three months). The
brothers' aggregate decline in CXR score was 0.027%/
year, FEV1 -0.018%/year, and FVC -0.012/year, compared
with aggregate declines for 57 patients homozygous for
the ΔF508 CFTR mutation in the same cohort of CXR
scores -0.065%/year, FEV1  -0.045%/year and FVC -
0.044%/year (unpublished data). While the brothers pre-
s e n t e d  w i t h  t h e  c l a s s i c a l  s y m p t o m s  o f  C F  a n d  a r e
homozygous for a CFTR mutation that should predict a
severe CF phenotype, they have a mild clinical course.
Discussion
According to CFTR nomenclature and sequence data,
3791delC is a frameshift CFTR mutation causing deletion
of the second base, cytosine, of codon 1220 in the CFTR
gene. This results in substitution of amino acids 1220
through 1226 in wild-type CFTR, TEGGNAI for
KKVEMPY, followed by production of a stop codon,
UAG, at position 1227, resulting in a truncated protein.
One case report [13] describes two CF patients with a
nonsense mutation in CFTR and mild pulmonary disease.
But there are no reports of in vitro functional analysis of
this 3791delC CFTR mutation. Thus, the conclusions we
draw regarding function of the 3791delC mutant CFTR
are by analogy to truncation mutants. Residue 1219 is the
first amino acid of the second nucleotide-binding domain
(NBD2) of CFTR. Numerous investigators have examined
the functionality of NBD2 mutants and C-terminal CFTR
truncation mutants. Although some truncation mutants
have normal maturation, most exhibit accelerated degra-
dation of mRNA and protein and aberrant trafficking
similar to ΔF508 CFTR [14] resulting in a significant
reduction in chloride channel activity [15]. Portions of
CFTR may dimerize and make some functional CFTR
within the respiratory epithelium. However, most muta-
tions that lead to premature termination signal cause
nonsense-mediated mRNA decay and, consequently,
absence of protein synthesis. These properties predict a
severe phenotype, especially in homozygous mutants.
However, our patients have a mild CF phenotype.
Conclusion
A prevailing idea in CF research is that the amount of
functional CFTR predicts clinical status; research focus
on gene therapy and upregulation of CFTR is based on
this premise. Our results indicate that disease severity in
CF can be variable even in patients with a CFTR muta-
tion that produces absent or aberrant protein. Ultimately,
we found a lack of correlation between the CFTR muta-
tion classification and lung function, which is likely par-
tially due to differential CFTR activity between the sweat
gland and lung epithelium, as well as the activity of modi-
fier genes and proteins. We suspect that the function of
the CFTR membrane transporter is entirely different
(that is, a non-transport function) or may differ with
respect to a substrate. Applicably, besides the transport of
substrates such as chloride and glutathione, CFTR has
non-transport functions, as illustrated by its role as aLevy et al. Journal of Medical Case Reports 2010, 4:117
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receptor for P. aeruginosa. Thus, differing effects of each
mutation on CFTR function may account for some of the
phenotypic heterogeneity and lack of correlation between
CFTR mutation and clinical course. The incongruously
benign course that these siblings present despite the
expectation that their 3791delC mutation produces little
or no functional CFTR, implies that factors outside
CFTR, likely modifier genes, have a potent compensatory
effect, and can steer the course away from its predicted
severity.
Consent
Both patients were lost to follow-up and efforts to trace
them and their family have proved futile. The Institu-
tional Review Board at Children's Hospital of Boston has
approved this case report for publication. Every effort has
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and we would not expect a reasonable patient or their
family to object to publication of this case report and any
accompanying images.
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